Concepedia

Lianhong Xu

LX

Statistics

Publications

32

Citations

1.5K

H-Index

21

Active since

1992

Affiliations

Gilead Sciences (United States)(Current)

Abbott Fund

Jiangsu University

Abbott (United States)

Korea Research Institute of Chemical Technology

Lianhong Xu is an author at Gilead Sciences (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

1992–2020

32

Publications

32

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

John O. Link, James G. Taylor, Lianhong Xu et al. · Journal of Medicinal Chemistry · 2013 · 292 citations

, , +17

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

Lianhong Xu, Hongtao Liu, Bernard P. Murray et al. · ACS Medicinal Chemistry Letters · 2010 · 200 citations

, , +14

Total synthesis of (.+-.)-FR-900482

Tohru Fukuyama, Lianhong Xu, Shunsuke Goto · Journal of the American Chemical Society · 1992 · 109 citations

, , +5

Transition metal catalyzed synthesis of 5-azaindoles

Lianhong Xu, Iestyn R. Lewis, Steven K. Davidsen et al. · Tetrahedron Letters · 1998 · 90 citations

, , +12

Total synthesis of (-)-tantazole B

Tohru Fukuyama, Lianhong Xu · Journal of the American Chemical Society · 1993 · 89 citations

, , +5

1–5 of 32